National Institutes of Health: Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
The registry lists 73 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 16 have results posted.
Phase 1 47Phase 2 29No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
- Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT01445080Phase 1/2Results posted
- Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
- Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01326728Results posted
- Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the BloodCompletedNCT00923910Phase 1/2Results posted
- Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell TransplantationCompletedNCT00859586Not applicableResults posted
- Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
- Peptide Vaccinations to Treat Patients With Low-Risk Myeloid CancersCompletedNCT00488592Phase 2Results posted
- Stem Cell Transplantation for Patients With Cancers of the BloodCompletedNCT00467961Phase 2Results posted
- Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic MalignancyCompletedNCT00433745Phase 2Results posted
- Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2Results posted
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
- Methods to Enhance the Safety and Effectiveness of Stem Cell TransplantsCompletedNCT00378534Phase 2Results posted
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT00070499Phase 2Results posted
- Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowCompletedNCT00003838Phase 2Results posted
- Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
- Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral InfectionsTerminatedNCT02231853Phase 1
- Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell TransplantationCompletedNCT02226861Phase 1
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Improving Blood Stem Cell Collection and Transplant ProceduresCompletedNCT01517035Phase 1/2
- Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib MesylateTerminatedNCT01426334Phase 1
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01159301Phase 1
- Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00459212Phase 1
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
- Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
- Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00316953Phase 1
- 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaTerminatedNCT00301769Phase 1
- Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
- Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaTerminatedNCT00101231Phase 1
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
- Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
- XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
- Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
- Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
- CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
- Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaCompletedNCT00079313Phase 2
- Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesCompletedNCT00077181Phase 1
- Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
- Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
- FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
- Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
- Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
- Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
- Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
- STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00015834Phase 1/2
- Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
- Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00006364Phase 2
- BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
- PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
- Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
- 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00003997Phase 1
- Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT00003694Phase 2
- Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00002574Phase 2
- The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic MalignanciesCompletedNCT00001432
- Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous LeukemiaCompletedNCT00001144Phase 2